留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

核苷酸适体在靶向给药系统中的应用进展

熊叶 台宗光 李强

熊叶, 台宗光, 李强. 核苷酸适体在靶向给药系统中的应用进展[J]. 药学实践与服务, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
引用本文: 熊叶, 台宗光, 李强. 核苷酸适体在靶向给药系统中的应用进展[J]. 药学实践与服务, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
XIONG Ye, TAI ZongGuang, Li Qiang. Application progress of nucleic acid aptamers in targeted drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
Citation: XIONG Ye, TAI ZongGuang, Li Qiang. Application progress of nucleic acid aptamers in targeted drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003

核苷酸适体在靶向给药系统中的应用进展

doi: 10.3969/j.issn.1006-0111.2015.06.003
基金项目: 国家自然科学基金项目(No.81170060)

Application progress of nucleic acid aptamers in targeted drug delivery system

  • 摘要: 适体,即体外合成筛选得到的能特异性地与靶分子结合的一段寡核苷酸序列。由于其独特的性质,在靶向给药系统中有着广阔的应用前景,目前已成为靶向给药研究领域的热点。综述了适体在靶向给药系统中的优势及其应用进展,并对其应用前景和面临的问题进行分析。
  • [1] Tan W, Wang H, Chen Y, et al. Molecular aptamers for drug delivery[J]. Trends Biotechnol, 2011, 29(12): 634-640.
    [2] Ozalp VC, Eyidogan F, Oktem HA. Aptamer-gated nanoparticles for smart drug delivery[J]. Pharmaceuticals, 2011, 4(8): 1137-1157.
    [3] Taouji S, Dausse E, Evadé L, et al. Advances in binder identification and characterisation: the case of oligonucleotide aptamers[J]. N Biotechnol, 2012, 29(5): 550-554.
    [4] Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy[J]. Chem Rev, 2007, 107(9): 3715-3743.
    [5] Lupold SE, Hicke BJ, Lin Y, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen[J]. Cancer Res, 2002, 62(14): 4029-4033.
    [6] Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates a new approach for targeting prostate cancer cells[J]. Cancer Res, 2004, 64(21): 7668-7672.
    [7] Bagalkot V, Farokhzad OC, Langer R, et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform[J]. Angew Chem Int Ed, 2006, 45(48): 8149-8152.
    [8] Kraus E, James W, Barclay AN. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function[J]. J Immunol, 1998, 160(11): 5209-5212.
    [9] Guo S, Tschammer N, Mohammed S, et al. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA[J]. Hum Gene Ther, 2005, 16(9): 1097-1110.
    [10] Khaled A, Guo S, Li F, et al. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology[J]. Nano Lett, 2005, 5(9): 1797-1808.
    [11] Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands[J]. Cell Signal, 2005, 17(10): 1183-1193.
    [12] Li N, Larson T, Nguyen HH, et al. Directed evolution of gold nanoparticle delivery to cells[J]. Chem Commun, 2010, 46(3): 392-394.
    [13] Prebet T, Lhoumeau A-C, Arnoulet C, et al. The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome[J]. Blood, 2010, 116(13): 2315-2323.
    [14] Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study[J]. P Natl Acad Sci USA, 2006, 103(32): 11838-11843.
    [15] Xiao Z, Shangguan D, Cao Z, et al. Cell-specific internalization study of an aptamer from whole cell selection[J]. Chem Eur J, 2008, 14(6): 1769-1775.
    [16] Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells[J]. Chem Bio Chem, 2009, 10(5): 862-868.
    [17] o'donoghue MB. A liposome-based nanostructure for aptamer directed delivery[J]. Chem Commun, 2010, 46(2): 249-251.
    [18] 胡 萍. 肿瘤发生和 MUC1 及 Survivin 研究进展[J]. 中国医药指南, 2013, 11(1): 69-70.
    [19] Altschuler Y, Kinlough CL, Poland PA, et al. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state[J]. Mol Biol Cell, 2000, 11(3): 819-831.
    [20] Gendler SJ. MUC1, the renaissance molecule[J]. J Mammary Gland Biol Neoplasia, 2001, 6(3): 339-353.
    [21] Ferreira CS, Cheung MC, Missailidis S, et al. Phototoxic aptamers selectively enter and kill epithelial cancer cells[J]. Nucleic Acids Res, 2009, 37(3): 866-876.
    [22] Do Kwon Y, Finzi A, Wu X, et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops[J]. P Natl Acad Sci USA, 2012, 109(15): 5663-5668.
    [23] Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy[J]. Mol Ther, 2008, 16(8): 1481-1489.
    [24] Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism[J]. Cancer Res, 2010, 70(21): 8617-8629.
    [25] Cao Z, Tong R, Mishra A, et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes[J]. Angew Chem Int Ed, 2009, 48(35): 6494-6498.
    [26] 胡艳玲, 史爱欣, 傅得兴, 等. 哌加他尼钠的药理作用和临床评价[J]. 中国新药杂志, 2007, 16(7): 573-576.
    [27] Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy[J]. Graef Arch Clin Exp, 2010, 248(7): 915-930.
    [28] Proske D, Gilch S, Wopfner F, et al. Prion-protein-specific aptamer reduces PrPSc formation[J]. Chem Bio Chem, 2002, 3(8): 717-725.
    [29] Jeon SH, Kayhan B, Ben-Yedidia T, et al. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin[J]. J Biol Chem, 2004, 279(46): 48410-48419.
    [30] Becker RC, Chan MY. REG-1, a regimen comprising RB-006, a Factor Ⅸa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis[J]. Curr Opin Mol Ther, 2009, 11(6): 707-715.
  • [1] 蒋薇薇, 杨峰.  离子导入给药的研究进展 . 药学实践与服务, 2023, 41(4): 212-217, 233. doi: 10.12206/j.issn.2097-2024.202208008
    [2] 林艳.  群体药动学应用于个体化给药的研究进展 . 药学实践与服务, 2015, 33(4): 293-297,346. doi: 10.3969/j.issn.1006-0111.2015.04.002
    [3] 曾棋平, 张晶, 刘志宏, 宋洪涛.  脂解模型在脂质给药系统体外评价中的应用研究进展 . 药学实践与服务, 2014, 32(2): 85-87. doi: 10.3969/j.issn.1006-0111.2014.02.002
    [4] 胡晓, 胡容峰, 白中稳.  聚乙烯醇衍生物作为水凝胶材料的应用研究进展 . 药学实践与服务, 2013, 31(3): 169-172,180. doi: 10.3969/j.issn.1006-0111.2013.03.002
    [5] 黎迎, 陆洋, 杜守颖, 马勇, 徐攀.  脉冲给药系统研究进展 . 药学实践与服务, 2012, 30(5): 326-330,343. doi: 10.3969/j.issn.1006-0111.2012.05.002
    [6] 万展, 周剑, 韩美娜, 杨峰.  微针透皮给药系统应用研究进展 . 药学实践与服务, 2012, 30(2): 86-88,142. doi: 10.3969/j.issn.1006-0111.2012.02.002
    [7] 陈婷, 鲁莹.  载抗肿瘤药物纳米靶向给药系统的研究进展 . 药学实践与服务, 2011, 29(3): 176-178,196.
    [8] 朱占洲, 孙青龑, 沈颂章, 何邦平, 王小燕.  绿色环保离子液体在药学研究中的应用进展 . 药学实践与服务, 2009, 27(4): 248-250.
    [9] 张申亮.  胶束电动毛细管色谱在中药化学成分分析中的应用 . 药学实践与服务, 2009, 27(1): 21-23,65.
    [10] 薛龙, 孙爱军.  恶性肿瘤靶向治疗方法的进展及应用 . 药学实践与服务, 2008, (2): 81-83.
    [11] 曹琴, 丁志建, 丁雪鹰, 高申.  非甾体抗炎药透皮给药的研究进展 . 药学实践与服务, 2003, (3): 147-149.
    [12] 陈鹰, 汤韧, 郑汉平, 田洪淘, 陈翠明.  新型经皮给药载体——传递体 . 药学实践与服务, 2001, (6): 339-342.
    [13] 何荣连.  甘露醇非静脉给药的临床应用 . 药学实践与服务, 2000, (1): 13-14.
    [14] 孙华君, 朱全刚, 胡晋红.  脂质体经皮给药研究进展 . 药学实践与服务, 1999, (4): 221-224.
    [15] 赵宏轩, 赵仲坤.  肺部给药及临床正确应用 . 药学实践与服务, 1991, (3): 42-44.
    [16] 鲁少云.  疏水性药物的鼻腔给药进展 . 药学实践与服务, 1990, (1): 59-61.
    [17] 任国喜, 杨瑞萍, 袁茵.  中药直肠给药治疗急腹症进展 . 药学实践与服务, 1989, (2): 24-25.
    [18] 周翰章.  给药系统进展概述(上) . 药学实践与服务, 1989, (2): 41-45.
    [19] 周翰章.  给药系统进展概述(下) . 药学实践与服务, 1989, (3): 75-79.
    [20] 冯友根.  可乐宁经皮控释给药的应用 . 药学实践与服务, 1986, (2): 26-28.
  • 加载中
计量
  • 文章访问数:  3036
  • HTML全文浏览量:  249
  • PDF下载量:  291
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-11-04
  • 修回日期:  2014-12-24

核苷酸适体在靶向给药系统中的应用进展

doi: 10.3969/j.issn.1006-0111.2015.06.003
    基金项目:  国家自然科学基金项目(No.81170060)

摘要: 适体,即体外合成筛选得到的能特异性地与靶分子结合的一段寡核苷酸序列。由于其独特的性质,在靶向给药系统中有着广阔的应用前景,目前已成为靶向给药研究领域的热点。综述了适体在靶向给药系统中的优势及其应用进展,并对其应用前景和面临的问题进行分析。

English Abstract

熊叶, 台宗光, 李强. 核苷酸适体在靶向给药系统中的应用进展[J]. 药学实践与服务, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
引用本文: 熊叶, 台宗光, 李强. 核苷酸适体在靶向给药系统中的应用进展[J]. 药学实践与服务, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
XIONG Ye, TAI ZongGuang, Li Qiang. Application progress of nucleic acid aptamers in targeted drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
Citation: XIONG Ye, TAI ZongGuang, Li Qiang. Application progress of nucleic acid aptamers in targeted drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
参考文献 (30)

目录

    /

    返回文章
    返回